Immunome, Inc.
NASDAQ: IMNM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Clay Siegall
- Employees
- 177
- Headquarters
- Bothell, United States
- IPO year
- 2020
- Market cap
- $1.9B
- Website
- https://www.immunome.com
Loading IMNM…
Loading profile data…Frequently asked questions about IMNM
What does Immunome, Inc. (IMNM) do?
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment...
Where does IMNM trade?
Immunome, Inc. (IMNM) trades on the NASDAQ.
What sector is IMNM in?
Immunome, Inc. (IMNM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immunome, Inc.?
Clay Siegall is the chief executive officer of Immunome, Inc. (IMNM).
Where is Immunome, Inc. headquartered?
Immunome, Inc. is headquartered in United States.
Does IMNM pay a dividend?
Immunome, Inc. (IMNM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMNM go public?
Immunome, Inc. (IMNM) completed its initial public offering in 2020.